110 related articles for article (PubMed ID: 9873554)
1. NMR and topochemical studies of peptidomimetic HIV-I protease inhibitors containing a cis-epoxide amide isostere.
Ro S; Baek SG; Lee B; Park C; Choy N; Lee CS; Son YC; Choi H; Koh JS; Yoon H; Kim SC; Ok JH
Bioorg Med Chem Lett; 1998 Sep; 8(18):2423-6. PubMed ID: 9873554
[TBL] [Abstract][Full Text] [Related]
2. Conformational studies of irreversible HIV-1 protease inhibitors containing cis-epoxide as an amide isostere.
Ro S; Baek SG; Lee B; Ok JH
J Pept Res; 1999 Sep; 54(3):242-8. PubMed ID: 10517162
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
Martin JL; Begun J; Schindeler A; Wickramasinghe WA; Alewood D; Alewood PF; Bergman DA; Brinkworth RI; Abbenante G; March DR; Reid RC; Fairlie DP
Biochemistry; 1999 Jun; 38(25):7978-88. PubMed ID: 10387041
[TBL] [Abstract][Full Text] [Related]
4. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
5. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
Ghosh AK; Krishnan K; Walters DE; Cho W; Cho H; Koo Y; Trevino J; Holland L; Buthod J
Bioorg Med Chem Lett; 1998 Apr; 8(8):979-82. PubMed ID: 9871524
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site.
Torbeev VY; Mandal K; Terechko VA; Kent SB
Bioorg Med Chem Lett; 2008 Aug; 18(16):4554-7. PubMed ID: 18657969
[TBL] [Abstract][Full Text] [Related]
7. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
[TBL] [Abstract][Full Text] [Related]
8. Solution conformations of KNI-272, a tripeptide HIV protease inhibitor designed on the basis of substrate transition state: determined by NMR spectroscopy and simulated annealing calculations.
Ohno Y; Kiso Y; Kobayashi Y
Bioorg Med Chem; 1996 Sep; 4(9):1565-72. PubMed ID: 8894113
[TBL] [Abstract][Full Text] [Related]
9. Heterocyclic HIV-1 protease inhibitors.
Baures PW
Org Lett; 1999 Jul; 1(2):249-52. PubMed ID: 10822561
[TBL] [Abstract][Full Text] [Related]
10. An efficient, stereoselective synthesis of the hydroxyethylene dipeptide isostere core for the HIV protease inhibitor A-792611.
Engstrom K; Henry R; Hollis LS; Kotecki B; Marsden I; Pu YM; Wagaw S; Wang W
J Org Chem; 2006 Jul; 71(14):5369-72. PubMed ID: 16808529
[TBL] [Abstract][Full Text] [Related]
11. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyethylamine isostere of an HIV-1 protease inhibitor prefers its amine to the hydroxy group in binding to catalytic aspartates. A synchrotron study of HIV-1 protease in complex with a peptidomimetic inhibitor.
Dohnálek J; Hasek J; Dusková J; Petroková H; Hradilek M; Soucek M; Konvalinka J; Brynda J; Sedlácek J; Fábry M
J Med Chem; 2002 Mar; 45(7):1432-8. PubMed ID: 11906284
[TBL] [Abstract][Full Text] [Related]
13. Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
Wu X; Ohrngren P; Ekegren JK; Unge J; Unge T; Wallberg H; Samuelsson B; Hallberg A; Larhed M
J Med Chem; 2008 Feb; 51(4):1053-7. PubMed ID: 18215014
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
[TBL] [Abstract][Full Text] [Related]
15. Endothiopeptide inhibitors of HIV-1 protease.
Yao S; Zutshi R; Chmielewski J
Bioorg Med Chem Lett; 1998 Mar; 8(6):699-704. PubMed ID: 9871586
[TBL] [Abstract][Full Text] [Related]
16. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease.
Jhoti H; Singh OM; Weir MP; Cooke R; Murray-Rust P; Wonacott A
Biochemistry; 1994 Jul; 33(28):8417-27. PubMed ID: 8031777
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres.
Benedetti F; Berti F; Budal S; Campaner P; Dinon F; Tossi A; Argirova R; Genova P; Atanassov V; Hinkov A
J Med Chem; 2012 Apr; 55(8):3900-10. PubMed ID: 22458611
[TBL] [Abstract][Full Text] [Related]
18. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
Tamamura H; Koh Y; Ueda S; Sasaki Y; Yamasaki T; Aoki M; Maeda K; Watai Y; Arikuni H; Otaka A; Mitsuya H; Fujii N
J Med Chem; 2003 Apr; 46(9):1764-8. PubMed ID: 12699395
[TBL] [Abstract][Full Text] [Related]
19. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
[TBL] [Abstract][Full Text] [Related]
20. Theoretical study on the mechanism of a ring-opening reaction of oxirane by the active-site aspartic dyad of HIV-1 protease.
Kóna J
Org Biomol Chem; 2008 Jan; 6(2):359-65. PubMed ID: 18175006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
